Unilever To Swallow GSK's Indian Horlicks Business
Unilever is to buy GlaxoSmithKline's Indian Horlicks nutrition business for around $3.8 billion (€3.4 billion), boosting the consumer goods group's position in a key emerging market.
The deal, announced on Monday, marks a further step by drugmaker GSK to streamline its business and follows a competitive auction in which Unilever saw off rival Nestle , as well as earlier interest from Coca-Cola.
The Main Asset
The transaction covers GSK's health food and drinks portfolio in India, Bangladesh and 20 other predominantly Asian markets. The main asset being sold is GSK's 72.5% stake in Indian-listed GlaxoSmithKline Consumer Healthcare.
Unilever said the €3.3 billion ($3.75 billion) it was paying would be paid in cash and shares in its subsidiary in India, Hindustan Unilever Limited (HUL).
GSK said its net proceeds from the deal, after tax and hedging costs, were expected to be around £2.4 billion (€2.7 billion).
Following the closure of the deal, GSK will own approximately 5.7% of HUL, which the British drugmaker intends to sell down in tranches.
In Line With Expectations
The price being paid for the GSK business, which includes the popular malt-based drinks Horlicks and Boost, is broadly in line with expectations. People familiar with the process had told Reuters it was likely to be for less than $4 billion (€3.5 billion).
Horlicks comfortably dominates the health-drinks market in India and Unilever is expected to try and give it a fresh lease of life, following a slowdown in sales growth in recent years.
GSK's decision to sell the business follows its $13 billion (€11.4 billion) acquisition of Novartis's stake in the two groups' consumer health joint venture earlier this year. GSK said at the time that selling Horlicks could support the funding of the Novartis buyout.